TAIPEI, Taiwan, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical need in pain management, ophthalmology, and oncology, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering in the United States of its American Depositary Shares (ADSs) representing shares of common stock. All ADSs to be sold in the offering will be offered by TLC. The number of ADSs to be offered and the price for the proposed offering have not yet been determined. TLC has applied to list its ADSs on The Nasdaq Global Market under the trading symbol "TLC".
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. CLSA Limited, H.C. Wainwright & Co., LLC, Janney Montgomery Scott LLC, and Laidlaw & Company (UK) Ltd. are acting as co-managers.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022; Email: email@example.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tel: +886 (0)2 2655 7377 ext 136
Source:Taiwan Liposome Company, Ltd.